Projects per year
Fingerprint
Dive into the research topics where Dwight Owen is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
Projects
- 1 Active
-
Cachexia-mediated FcRn Modulation and Its Impact on Anti-PD1 Therapy in Lung Cancer
Phelps, M. M. A., Coss, C., Owen, D. & Mace, T.
08/8/22 → 07/31/24
Project: Research
-
Antibody drug clearance: an underexplored marker of outcomes with checkpoint inhibitors
Guo, Y., Remaily, B. C., Thomas, J., Kim, K., Kulp, S. K., Mace, T. A., Ganesan, L. P., Owen, D. H., Coss, C. C. & Phelps, M. A., Mar 1 2024, In: Clinical Cancer Research. 30, 5, p. 942-958 17 p.Research output: Contribution to journal › Review article › peer-review
-
A Phase 2 Trial of Primary Tumor Stereotactic Body Radiation Therapy Boost Before Concurrent Chemoradiation for Locally Advanced Non-Small Cell Lung Cancer
Williams, T. M., Miller, E., Welliver, M., Brownstein, J., Otterson, G., Owen, D., Haglund, K., Shields, P., Bertino, E., Presley, C., He, K., Jacob, N. K., Walston, S., Pan, J., Yang, X., Knopp, M., Essan, J. K., McElroy, J., Mo, X., McElroy, S., & 2 others , 2024, (Accepted/In press) In: International Journal of Radiation Oncology Biology Physics.Research output: Contribution to journal › Article › peer-review
-
Author Correction: Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial (Nature Medicine, (2022), 28, 10, (2155-2161), 10.1038/s41591-022-01962-5)
LCMC study investigators, Jan 2024, In: Nature Medicine. 30, 1, p. 303 1 p.Research output: Contribution to journal › Comment/debate
Open Access -
Case report: Hypereosinophilia in non-small cell lung cancer
Kwon, H., Li, M., Sheldon, J. D., Jones, N., Crestani, N. G., Li, Z. & Owen, D. H., Mar 2024, In: Current Problems in Cancer: Case Reports. 13, 100275.Research output: Contribution to journal › Article › peer-review
Open Access -
Consolidation Osimertinib Versus Durvalumab Versus Observation After Concurrent Chemoradiation in Unresectable EGFR-Mutant NSCLC: A Multicenter Retrospective Cohort Study
Nassar, A. H., Kim, S. Y., Aredo, J. V., Feng, J., Shepherd, F., Xu, C., Kaldas, D., Gray, J. E., Dilling, T. J., Neal, J. W., Wakelee, H. A., Liu, Y., Lin, S. H., Abuali, T., Amini, A., Nie, Y., Patil, T., Lobachov, A., Bar, J., Fitzgerald, B., & 37 others , 2024, (Accepted/In press) In: Journal of Thoracic Oncology.Research output: Contribution to journal › Article › peer-review
3 Scopus citations